BRAF-induced MAPK activation cannot be controlled with MEK inhibition only and requires combined MEK and BRAF inhibition, whereas the activation can be controlled reasonably well in RAS mutation-initiated cancers [15,16,22]. The gene discussed is BRAF; the disease is cancer.